View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 12, 2021updated 12 Jul 2022 11:05am

Sanofi’s meningococcal disease jab meets all endpoints in Phase III trial

MenQuadfi induces greater immune responses to serogroup C compared with NeisVac-C and Nimenrix in healthy toddlers. 

Sanofi has reported that its single-dose vaccine, MenQuadfi, met all primary and secondary endpoints in Phase III MEQ00065 study in healthy toddlers for preventing invasive meningococcal disease (IMD), a fatal illness.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The head-to-head comparative, multi-centre Phase III trial was carried out in Germany, Finland and Denmark.

It compared the immune response against meningococcal serogroup C and analysed the safety of MenQuadfi in healthy toddlers aged 12 to 23 months as against quadrivalent ACWY vaccine, Nimenrix and monovalent C vaccine, NeisVac-C.

Trial data showed that MenQuadfi stimulated greater immune responses to serogroup C according to geometric mean antibody titers (GMTs) versus NeisVac-C in healthy toddlers.

Furthermore, the trial demonstrated that switching from monovalent C to MenQuadfi in toddlers can be done with no compromise to serogroup C protection.

Compared to Nimenrix, MenQuadfi had superior immune responses to serogroup C depending on GMTs as well as seroprotection rates.

Sanofi noted that MenQuadfi is the first quadrivalent ACWY vaccine to achieve a superior immune response against this serogroup in this population.

The three vaccines tested in the trial had comparable safety profiles.

Sanofi will publish complete data from the Phase III trial in the fourth quarter of this year.

Sanofi Pasteur global medical head Dr Su-Peing Ng said: “The results of our head-to-head Phase III study are clear and add to our robust evidence demonstrating the strong profile of MenQuadfi against meningococcal disease caused by serogroups A, C, W and Y from toddlers to adults.

“These data represent an important public health milestone in our efforts to advance protection against meningococcal meningitis and in support of the World Health Organization’s ambition to defeat this disease by 2030.”

The US Food and Drug Administration currently licensed the vaccine for preventing IMD in toddlers aged two years or above.

MenQuadfi is also approved by the European Commission, Iceland and UK, among other countries, for preventing invasive meningococcal ACWY disease in toddlers aged two years or above.

The vaccine can be given as a single dose and supports primary and booster inoculation to a broader age group, from two-year toddlers to children, adolescents, adults and even the elderly.

Last month, Sanofi Pasteur and Translate Bio commenced a Phase I clinical trial in the US to assess an investigational mRNA-based vaccine candidate against seasonal influenza.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena